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bypass (CPB). This fact was impressively documented by the
case presented.
There is, however, one error in the text that bears comment.
Although the article indeed presents the first clinical case of
C1INH substitution in a patient with HANE during heart
surgery, it was not the first time that C1INH had been given
during CPB. In 1998, we1 published the results of a group of
patients receiving C1INH (Berinert; Aventis, Behring,
Germany) to treat severe cardiocirculatory failure after emer-
gency coronary revascularization for unsuccessful percuta-
neous transluminal coronary angioplasty. In these patients,
postoperative depression of myocardial function had to be
attributed to myocardial stunning caused by ischemia and
reperfusion. From the knowledge of experimental findings
demonstrating a cardioprotective effect of C1INH,2,3 we used
the inhibitor concentrate as a rescue therapy after all conven-
tional methods (ie, long reperfusion on CPB, catecholamines,
inotropic dilators, and aortic counterpulsation) had failed to
stabilize the patients’ circulatory situation. All patients sur-
vived the intervention and had an uneventful postoperative
course.
The effects of C1INH substitution in these particular
patients may not have been exclusively limited to the suc-
cessful treatment of ischemia-reperfusion phenomena. The
coincidence of a 4- to 6-hour period of preoperative
ischemia, depressed myocardial function, and CPB could
have resulted in a fatal combination, including a strong
inflammatory response. Because reperfusion injury and the
inflammatory response to CPB are both complement-
dependent, local and systemic effects of complement inhi-
bition may have contributed to the rapid clinical improve-
Although in recent years C1INH has been restricted to sub-
stitution therapy in patients with HANE,4 increasing evidence
now exists that the inhibitor may be helpful in special clini-
cal situations leading to an increased capillary permeability.5
In our opinion, these promising results obtained during
ischemia-reperfusion, sepsis, or CPB should encourage the
performance of clinical and experimental trials to further
clarify the physiologic effects and possible therapeutic role of
complement inhibition.
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C1 esterase inhibitor concentrate during surgery
with cardiopulmonary bypass: Is there an indica-
tion beyond substitution therapy in patients with
hereditary angioneurotic edema?
To the Editor:
We read with interest the article by Alvarez, titled
“Successful Use of C1 Esterase Inhibitor Protein in a Patient
With Hereditary Angioneurotic Edema Requiring Coronary
Bypass Surgery” (J Thorac Cardiovasc Surg 2000;119:168-
71). We agree that substitution of C1 esterase inhibitor
(C1INH) is the only efficacious therapy to prevent fatal com-
plications in patients with hereditary angioneurotic edema
(HANE) undergoing cardiac surgery with cardiopulmonary
